ICT 03
Alternative Names: ICT03Latest Information Update: 28 Aug 2024
At a glance
- Originator ImCheck Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in France (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Solid-tumours in France (Parenteral)
- 03 Jul 2020 ICT 03 is available for licensing as of 03 Jul 2020. https://www.imchecktherapeutics.com/